<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577028</url>
  </required_header>
  <id_info>
    <org_study_id>HPN424-1001</org_study_id>
    <nct_id>NCT03577028</nct_id>
  </id_info>
  <brief_title>Study of HPN424 in Patients With Advanced Prostate Cancer</brief_title>
  <official_title>A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harpoon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harpoon Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, Phase 1/2a, study of HPN424 as monotherapy to assess the safety, tolerability
      and PK in patients with advanced prostate cancer refractory to androgen therapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities</measure>
    <time_frame>Up to study day 21</time_frame>
    <description>In Part 1, measure incidence of dose limiting toxicities measured by adverse events and serious adverse events by dose level.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental: HPN424-1001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 (Dose Escalation), HPN424 will be administered once weekly via IV infusion with dose escalation until an estimated therapeutic dose level has been reached.
In Part 2 (Dose Expansion), patients will receive HPN424 at the recommended phase 2 dose(s) established in Part 1 of the study. Study procedures will be the same in Part 1 and Part 2 of the study. Additional expansion cohorts of up to 18 patients per expansion cohort may be added.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPN424</intervention_name>
    <description>In Part 1 (Dose Escalation), HPN424 will be administered once weekly via IV infusion. In Part 2 (Dose Expansion), HPN424 will be administered at the recommended phase 2 dose(s) once weekly via IV infusion.</description>
    <arm_group_label>Experimental: HPN424-1001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male patients ≥18 years of age

          2. Histologically or cytologically confirmed adenocarcinoma of the prostate

          3. Progressive metastatic castrate-resistant prostate cancer (mCRPC):

               1. Serum testosterone levels less than 50 ng/dL (or ≤0.50 ng/mL or 1.73 nmol/L)
                  within 28 days prior to start of study drug

               2. Radiographic evidence of metastatic disease

               3. Disease progression on the prior systemic regimen

          4. Must have received at least 2 prior systemic therapies approved for mCRPC

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          6. Adequate bone marrow function

          7. Able to read, understand and provide written informed consent

        Key Exclusion Criteria:

          1. Previously treated or current brain metastases

          2. Untreated spinal cord compression. Participants must be neurologically stable off
             steroids for at least 4 weeks prior to first dose of study drug

          3. Concurrent treatment with anti-tumor necrosis factor (TNF) alpha therapies, systemic
             corticosteroids (prednisone dose &gt;10 mg per day or equivalent), or other immune
             suppressive drugs within the 2 weeks prior to first dose of study drug

          4. History of or known or suspected autoimmune disease (exception(s): patients with
             vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism
             that is clinically euthyroid at Screening are allowed)

          5. History of clinically significant cardiovascular disease such as symptomatic
             congestive heart failure (CHF), myocardial infarction within 6 months before first
             dose of study drug, history of thromboembolic event within 3 months before first dose
             of study drug

          6. Known active or chronic hepatitis B or hepatitis C as demonstrated by hepatitis B
             surface antigen (HBsAg) positivity and/or anti-hepatitis C virus (HCV) positivity,
             respectively, or known history of human immunodeficiency virus (HIV) seropositive
             status

          7. Clinically active liver disease, including liver cirrhosis that is Child-Pugh class B
             or C

          8. Second primary malignancy that has not been in remission for at least 3 years.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Harpoon Therapeutics</last_name>
    <phone>1-650-689-1047</phone>
    <email>HPN4241001@harpoontx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of California San Francisco</last_name>
      <email>HDFCCC.CIP@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Gao, MD</last_name>
      <phone>617-724-5197</phone>
      <email>XGAO4@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital-Columbia University Medical Center.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget James</last_name>
      <phone>212-304-5543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaadi Tabatabaei</last_name>
      <phone>503-494-6179</phone>
      <email>tabataba@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cannon Research Institute</last_name>
    </contact>
    <contact_backup>
      <phone>1-844-482-4812</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Crowley Cancer Research</last_name>
      <phone>972-566-3000</phone>
      <email>Referral@MaryCrowley.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahesha Ganegoda</last_name>
      <phone>+44 (0)20 8642 6011</phone>
      <phone_ext>1448</phone_ext>
      <email>Mahesha.Ganegoda@icr.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

